Ophthalmology Times Newsletter

To view this email as a web page, click here.

Pearls for managing care of high-risk uveal melanoma patients

When it comes to adjuvant treatment for high-risk uveal melanoma, physicians are turning to sunitinib malate (Sutent, Pfizer)—an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and immune modulating effect—as a viable option, according to Carol L. Shields, MD, chief of ocular oncology service at Wills Eye Hospital, Philadelphia.

Learn more

Ophthalmology can ‘adopt’ technologies from other specialties

Many medical specialties share medications and technologies, from various classes of drugs to diagnostic testing and surgical instruments. Patients can benefits as physicians take advantage of new treatment options.

Read on

Controlling adult glaucoma with cataract surgery, stent

As the second-leading cause of blindness worldwide, more than 3 million Americans suffer from glaucoma. A new procedure aims to relieve the mechanism and symptoms of the disease and help prevent blindness.

Find out more

New IOL design trends avoid negative dysphotopsias

Examining comparable surgical methods for IOL dislocation

Intraoperative surgical methods key to AMD treatment

Treating dry eye with recombinant human nerve growth factor

Gene therapy for LHON: Deciphering phase III data

Budding technology could be an OCT analysis game-changer

Weigh risk, benefits of cataract surgery for your patients

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.